絞り込み

16639

広告

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

著者 Cohen AT , Ay C , Hainaut P , Décousus H , Hoffmann U , Gaine S , Coppens M , da Silva PM , Castro DJ , Amann-Vesti B , Brüggenjürgen B , Levy P , Bastida JL , Vicaut E , Laeis P , Fronk EM , Zierhut W , Malzer T , Bramlage P , Agnelli G ,
Thromb J.2018 ; 16():9.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (131view , 0users)

Full Text Sources

Medical

Other Literature Sources

Venous thromboembolism (VTE, including deep vein thrombosis [DVT] and pulmonary embolism [PE]) has an annual incidence rate of 104-183 per 100,000 person-years. After a VTE episode, the two-year recurrence rate is about 17%. Consequently, effective and safe anticoagulation is paramount. Edoxaban is a direct oral anticoagulant (DOAC) approved VTE treatment. Current safety and efficacy data are derived from clinical trials, and information about treatment durations beyond 12 months are not available.
PMID: 29719492 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード